← All trials
NCT06216340
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2024
- Primary completion
- Oct 1, 2026
- Completion date
- Oct 1, 2026
- First posted
- Jan 22, 2024
- Last posted
- Jan 22, 2024
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The First People's Hospital of ChangzhouLead sponsor
- Nanjing Medical UniversityOfficial
- Nanjing Medical UniversityOfficial
- The First People's Hospital of LianyungangCollaborator
- Nanjing Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- The First People's Hospital of LianyungangOfficial
- Yanshi People’s HospitalOfficial
- Jiangsu UniversityOfficial
- Wuxi People's HospitalCollaborator
- Soochow UniversityOfficial
- Soochow UniversityOfficial
- Xuzhou Medical UniversityOfficial
- Jiangsu UniversityCollaborator
- Wuxi People's HospitalOfficial
- Soochow UniversityCollaborator
- Xuzhou Medical UniversityCollaborator
- Soochow UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.